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Objective
To investigate if short-term treatment with dutasteride
(8 weeks) before bipolar transurethral resection of the
prostate (B-TURP) can reduce intraoperative bleeding,
as dutasteride a dual 5α-reductase inhibitor (5-ARI)
blocks the conversion of testosterone into its active form
dihydrotestosterone (DHT), and reduces prostate volume
and prostate-specific antigen (PSA) levels, while increasing
urinary flow rate.
Patients and Methods
In all, 259 patients were enrolled and randomised to two
groups: Group A, receiving placebo and Group B, receiving
dutasteride (0.5 mg daily for 8 weeks). Blood samples were
taken before and after B-TURP for serum chemistry
evaluation. In particular we evaluated blood parameters
associated with blood loss [haemoglobin (Hb) and haematocrit
(Ht)] and prostate vascularity [vascular endothelial growth
factor (VEGF) immunoreactivity and microvessel density
(MVD) using cluster of differentiation 34 (CD34)
immunoreactivity].
Results
Total testosterone, DHT, PSA level and prostate volume were
evaluated and with the exception of DHT and PSA level there
was no statistically significant differences between the groups.
When comparing changes in Hb and Ht between Group A
and Group B before and after B-TURP, there was a statistically
significant difference only in patients with large prostates of
≥50 mL (ΔHb 3.86 vs 2.05 g/dL and ΔHt 4.98 vs 2.64%, in
Groups A and B, respectively). There was no significant
difference in MVD and VEGF index in prostates of <50 mL,
conversely in large prostates the difference become statistically
significant.
Conclusions
Dutasteride was able to reduce operative and perioperative
bleeding only in patients with large prostates (≥50 mL) that
underwent B-TURP. Our findings are confirmed by Hb
and Ht values reported before and after the B-TURP and





Benign prostatic enlargement and the histologically confirmed
diagnosis of BPH is the most important cause of LUTS. BPH
has an incidence of up to 40% in men in their fifth decade and
increases with age [1].
The nuclear-bound steroid enzyme 5α-reductase, primarily in
the prostatic stroma cells, converts testosterone into its active
form, dihydrotestosterone (DHT). Two isoforms of this
enzyme are present in the human body: type 1 mainly
expressed in the liver and skin and type 2 mainly expressed
and active in the prostate. 5α-reductase inhibitors (5-ARIs)
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block this conversion and have the ability to reduce prostate
volume by 18–28%, reduce PSA levels by 50%, increase
urinary flow and decrease the incidence of urinary
retention [2,3]. 5-ARIs should be offered to patients with
moderate-to-severe BPH and with an enlarged prostate
(>40 mL) to prevent disease progression. 5-ARIs, through
their action, decrease the activity of androgen-controlled
growth factors finally responsible for angiogenesis and
theoretically reduce operative prostatic bleeding [4]. In
particular finasteride decreases vascular endothelial growth
factor (VEGF) expression as well as microvessel density
(MVD) in prostatic tissue [5].
Dutasteride is a 5-ARI that acts specifically on both isotypes of
5α-reductase (type 1 and 2); finasteride, on the other hand, is
selective for isoenzyme type 2. Dutasteride, in comparison
with finasteride, is a 45-fold greater inhibitor of type 1 and
2.5-fold greater inhibitor of type 2 5α-reductase [6,7].
Dutasteride achieves a serum DHT reduction of >90%,
whereas finasteride results in a suppression of up to 70% [8].
Considering the better DHT suppression by dutasteride,
we speculated that it may also have a greater effect on
vascularisation. Ku et al. [9] reported that in the prostate of
rats, treated with at least 4 weeks dutasteride, there is lower
expression of VEGF and hypoxia-inducible factor 1α
(HIF-1α), two main factors correlated with vascularisation.
5-ARIs can be offered to men with moderate-to-severe LUTS
with an enlarged prostate to prevent disease progression but
due to the slow onset of action are suitable only for long-term
treatment (many years).
In accordance with European Association of Urology
guidelines, TURP remains the ‘gold standard’ surgical
treatment for LUTS secondary to BPH in prostates with a
volume of 30–80 mL. TURP can decrease most symptoms,
with improvement in all urodynamic parameters and is
superior to medical therapy [10]. One of the main intra- and
perioperative complications is haemorrhage that can lead to
bladder clot retention and an incidence of blood transfusion
of up to 8.4% [11]. Bipolar TURP (B-TURP), with the
introduction of plasmakinetic bipolar technology, represents
an important improvement of the traditional TURP.
Monopolar TURP vs B-TURP is reported to have almost the
same efficacy, while the overall incidence of side-effects is
lower for B-TURP (28.6% vs 15.5%) [12]. The main
advantages are less bleeding, with reduced fluid absorption,
reduction of clot retention with lower blood transfusion rate
and virtual elimination of transurethral resection syndrome
due to the use of saline irrigation.
Assuming that dutasteride reduces prostatic vascularisation,
and considering B-TURP as the ‘gold standard’ treatment in
patients with BPH with LUTS, we investigated if a short-term
treatment with dutasteride (8 weeks) before B-TURP could
reduce intraoperative bleeding.We also evaluated VEGF and
cluster of differentiation 34 (CD34), an immunohistochemical
marker of the MVD, in resected prostatic tissue.
Patients and Methods
Between April 2011 and May 2013, 259 patients with a mean
(range) age of 68 (60–81) years were randomised to receive
daily 0.5 mg dutasteride or placebo for 8 weeks before
B-TURP. This was a single-centre study and all patients were
referred to the Department of Urology, Policlinico Umberto I
Sapienza Rome University. Men in Group A received placebo
pretreatment and those in Group B received dutasteride
(0.5 mg daily for 8 weeks) in a 1:1 ratio. For better evaluation
of the results, randomisation was stratified by prostate volume
(<50 and ≥50 mL). All the patients enrolled were treated
before B-TURP with α-blockers. Every patient, the day before
B-TURP, underwent a TRUS of the prostate to evaluate the
exact volume of the gland. Moreover, 1 h before B-TURP,
blood was drawn for serum chemistry evaluation. Patients
taking NSAIDs, anticoagulant or antiplatelet drugs
discontinued 2 weeks before B-TURP. All surgical procedures
were carried out under spinal anaesthesia, the surgeon used a
24-F resectoscope (Karl Storz, Tuttlingen, Germany) at low
pressure with continuous flow and at the end a three-way
18–22 F catheter was placed. Intravenous hydration was
started at the beginning of anaesthesia (1000 mL) and was
continued for the day of the procedure and maintained
constant at 1500 mL (100 mL/h). At 48 h after B-TURP a
second blood sample was drawn.
Exclusion criteria included: patients with renal function
impairment (blood creatinine >145 μmol/L) due to its effect
on blood clotting; patients with an alteration of coagulation
parameters [international normalised ratio (INR) >1.3] or any
kind of bleeding disorders; patients that, in the past, had
already undergone any kind of prostate surgery; patients that
had already assumed a different scheme, period or dosage of
any kind of 5-ARI; refusal to sign the informed consent.
Considering the aforementioned criteria, 19 patients were
excluded.
For the study outcomes the following parameters were
evaluated: haemoglobin (Hb) and haematocrit (Ht) before and
after B-TURP, PSA level, total testosterone (TT) and DHT
levels, and we also calculated resected prostate volume and
B-TURP duration. Resected prostate chips were histologically
analysed ensuring separation from those extracted from the
urethra. Afterwards, the material was stained with monoclonal
antibodies directed against CD34 and VEGF. In particular,
a CD34 value and a VEGF index were obtained. Tissue
specimens, fixed in 10% buffered formalin and embedded in
paraffin, were stained with haematoxylin and eosin. Sections
were cut and slides were dewaxed in xylene and rehydrated
through a graded series of ethanols. Heat-induced epitope
retrieval was carried out by immersing the slides in citrate
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buffer (pH 6) and microwaving at 600 W for 20 min before
rinsing with PBS. Endogenous peroxidase activity was
quenched by incubating the sections in 1% hydrogen peroxide.
Nonspecific binding sites were then blocked by pre-incubating
with 20% normal serum and 1% BSA in PBS/0.3% Triton
X-100 (Union Carbide, Dow Corporation, Midland, MI, USA)
for 20 min at room temperature. Sections were incubated
with polyclonal rabbit anti-VEGF antibody at a concentration
of 1:50, as well as monoclonal murine anti-CD34 at a
concentration of 1:20. After washing with 0.25% BSA and
0.05% polysorbate 20 in PBS, sections were incubated with
biotinylated secondary pan-specific antibody at 1:500 for 1 h at
room temperature. Sections were again washed in PBS with
0.05% polysorbate 20, then incubated with horseradish
peroxidase and conjugated streptavidin-biotin complex for
45 min. All sections were again washed in PBS with 0.05%
polysorbate 20. Immunoreactivity was then visualised by
adding hydrogen peroxide as an enzyme substrate, in the
presence of 0.05% 3,3′-diaminobenzidine. Nuclei were then
lightly counterstained with Harris’s haematoxylin. All the areas
of most intense neovascularisation were evaluated by scanning
at low magnification (×10–100), avoiding areas with
lymphocytic infiltration or fibrosis, and seven to eight sections
for each patient were included (Figs 1, 2). Any brown-staining
endothelial cell (CD34-positive) containing a visible nucleus
and clearly separate from adjacent microvessels, epithelial
cells, and other connective tissue elements, was considered a
single, countable microvessel, without requirement for a
lumen or the presence of erythrocytes. The microvessels were
counted in a 0.74 mm2 area. VEGF immunoreactivity was
scored for the percentage of stained epithelial glandular and
endothelial cells, as 0, 1+, 2+, or 3+, according to staining
intensity [13]. A hypertrophic area with any degree of staining
was scored as VEGF-positive. Hyperplastic areas that were
VEGF-positive and VEGF-negative were assigned the score of
the area with strongest staining.
Spontaneously reported adverse events or those noted by
the investigator were recorded throughout the study.
Ethical committee approval was obtained and all treatments
applied are part of routine standard care; the registration
number is 21 and was obtained on 7th April 2014. The study
was conducted in line with European Urology and Good
Clinical Practice guidelines, with ethical principles laid down
in the latest version of the Declaration of Helsinki. Every
patient signed an informed consent to participate in the study.
Statistical analysis was carried out with BMDP statistical
software, version 7 (Statistical Solutions, Saugus, MA, USA)
and SPSS (Chicago, IL, USA; version 15.00 for Windows). For
all analyses, we used two-sided tests, with P < 0.05 considered
to indicate statistical significance.
Continuous variables are reported as the mean (SD) and
compared between groups using Student’s t-test for
independent samples or using the Welch-corrected t-test in
case of heteroscedasticity. Categorical variables are reported as
the number of occurrences and percentages.
Analysis of covariance (ANCOVA) was used to assess the
significance of variation in Hb and Ht levels before and after
B-TURP. In this analysis, Group (placebo vs dutasteride) was
used as fixed factor and preoperative values of outcome
variables were entered as covariates. Results of ANCOVA models
Fig. 1 Placebo group – immunohistochemical evaluation of prostatic
tissue with higher expression of MVD (CD34) and brown stained spot
representing vessels, ×100.
Fig. 2 Dutasteride group – immunohistochemical evaluation of prostatic
tissue with lower expression of MVD (CD34) and brown stained spot
representing vessels, ×100.
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are expressed in terms of estimated marginal means with
95% CIs.
A post hoc power analysis showed that a sample size of 120
per group (for each level of the stratification factor) would
allow the detection of a medium effect size (Cohen’s d = 0.5)
with a power of 80% using a two-tailed t-test and a
significance level of 0.05.
Results
Of the 259 enrolled patients, 19 did not meet inclusion
criteria. Both Group A (placebo pretreatment) and Group B
(dutasteride pretreatment) consisted each of 120 eligible
patients. TT, DHT, PSA levels and prostate volume were
evaluated and with the exclusion of DHT and PSA levels there
were no statistically significant differences between the groups
(Table 1). All patients underwent B-TURP and the mean (SD)
operative time was 50 (10) min in Group A and 48 (13) min
in Group B (P = 0.23). After B-TURP the volume removed
was evaluated and was, respectively, 31.58 (9.87) mL in Group
A and 32.15 (8.36) mL in Group B (P = 0.88).
Hb and Ht values, evaluated 1 h before and 48 h after the
B-TURP, were correlated between Group A and B in
accordance with prostate size, and in particular we compared
prostates with a volume <50 mL and those with a volume
≥50 mL. Considering small prostates (<50 mL) and according
to the ANCOVA results, the reduction in Hb values from before
to after B-TURP was 2.41 g/dL (95% CI 1.39–3.43) in Group
A and 1.92 g/dL (95% CI 1.00–2.84) in Group B (difference
between groups: 0.49 g/dL, 95% CI –0.26 to 1.24; P = 0.454). A
decrease in Ht levels was also seen both in the placebo group
(2.22%; 95% CI 1.77–2.67) and the dutasteride group (1.95%;
95% CI 1.50–2.40) without a statistically significant treatment
effect (difference between groups: –0.27%; 95%CI –0.91 to
0.38; P = 0.411).
In men with prostates ≥50 mL the reduction in Hb was
significantly lower in Group B (2.05 g/dL; 95% CI 1.47–2.61)
than in Group A (3.86 g/dL; 95% CI 3.29–4.43) with a
treatment effect equal to –1.81 g/dL (95% CI –2.62 to –1.0;
P < 0.05); Group B was also characterised by a significantly
lower reduction in Ht levels vs Group A (2.64% vs 4.98%;
difference between groups: –2.34%; 95% CI –3.51 to –1.17;
P < 0.05).
The mean (SD) MVD and VEGF index in prostates of <50 mL
were 18.64 (1.12) and 2.09 (0.48) in Group A and 17.04 (0.40)
and 1.73 (0.36) in Group B respectively, without a statistically
significant difference. The mean (SD) MVD and VEGF index
in prostates of ≥50 mL were 24.17 (1.80) and 6.73 (0.95) in
Group A and 19.49 (0.44) and 2.44 (0.49) in Group B (both
P < 0.05). All results are listed in Table 2.
Discussion
Benign prostatic enlargement, caused by hyperplasia of both
stromal and acinar cells in the periurethral transition zone,
is also characterised by an increase in vascularisation.






Patients, n 120 120
Mean (range) age, years 67 (61–78) 68 (60–81) 0.9
Mean (SD):
Body mass index, kg/m2 27.34 (8.5) 28.12 (7.6) 0.21
PSA level, ng/mL 4.48 (3.2) 2.33 (1.15) <0.05
TT, ng/dL 525 (284) 588 (335) 0.34
DHT, ng/dL 54 (33) 5 (4) <0.05
Prostate volume, mL 60.35 (35.86) 61.15 (34.73) 0.79
Volume removed, mL 31.58 (9.87) 32.15 (8.36) 0.88
Operating time, min 50 (10) 48 (13) 0.23
Table 2 Blood parameters and vascularisation in prostates of <50 and ≥50 mL.










Patients, n 39 38 81 82
Mean (SD) Hb, g/dL:
before B-TURP 14.37 (2.12) 13.92 (2.12) 0.48 14.30 (2.10) 14.01 (2.08) 0.54
after B-TURP 12.34 (1.86) 12.19 (2.12) 0.35 10.50 (2.49) 11.91 (2.15) <0.05
ΔHb, g/dL (95% CI)* 2.41 (1.39–3.43) 1.92 (1.00–2.84) 0.45 3.86 (3.29–4.43) 2.05 (1.47–2.61) <0.05
Mean (SD) Ht, %:
before B-TURP 43.15 (3.20) 42.48 (4.23) 0.67 43.00 (3.20) 42.66 (4.15) 0.60
after B-TURP, % 40.78 (3.01) 40.15 (4.77) 0.57 38.20 (3.84) 40.16 (3.24) <0.05
ΔHt, % (95% CI)* 2.22 (1.77–2.67) 1.95 (1.50–2.40) 0.41 4.98 (4.16–4.80) 2.64 (1.82–3.46) <0.05
Mean (SD):
MVD 18.64 (1.12) 17.04 (0.40) 0.09 24.17 (1.80) 19.49 (0.44) <0.05
VEGF index 2.09 (0.48) 1.73 (0.36) 0.09 6.73 (0.95) 2.44 (0.49) <0.05
*Results are expressed as estimated marginal means (ANCOVA model) with 95% CIs.
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Following our previous experience with finasteride, used as a
pretreatment to reduce bleeding during monopolar TURP,
we decided to evaluate if dutasteride, a theoretically more
effective drug, was able to achieve better results. Furthermore,
differing from the previous trial we used the latest surgical
technique, B-TURP [14].
Considering the results of our present trial we can
conclude that a short pretreatment with dutasteride is able
to reduce B-TURP bleeding but only when treating large
prostates with a volume of ≥50 mL. In particular, in this
subgroup of patients, there is a statistically significant
difference in ΔHb and ΔHt (3.86 vs 2.05 g/dL and 4.98 vs
2.64%, respectively), which favours dutasteride-treated
patients. The present results are confirmed by CD34 and
VEGF evaluations.
Looking at the blood parameters of the patients in both
groups, the first consideration is that 8 weeks of dutasteride is
able to reduce DHT by ≈90% and have only a slight action on
TT (not statistically significant).When comparing the DHT
values after pretreatment with finasteride, it is evident that
dutasteride pretreatment achieves a larger reduction and this
is correlated with the capability of the first to inhibit only
5α-reductase type 2, while the second has an action on both
types (1 and 2). Amory et al. [15] reported that dutasteride and
finasteride reduce DHT by 94% and 73%, respectively, with
transiently increased testosterone.
Although the clinical role of dual inhibition remains unclear,
it is established that 5-ARIs induce apoptosis of prostate
epithelial cells leading to gland volume reduction and PSA
level decreases [16]. Analysing the PSA levels after 8 weeks
of therapy with the 5-ARI, we found that there was a
reduction of ≈48% compared with the placebo group. In the
literature it is reported that 5-ARIs are able to reduce PSA
levels by ≈50% [2,3]. Prostate volume, the volume removed
and operative time were about the same for the two groups.
It has been reported that 5-ARIs are able to reduce LUTS by
15–30%, decrease prostate volume by 18–28% and increase
maximum urinary flow rate by 1.5–2.0 mL/s, but only after a
long period of treatment (2–4 years) [10]. Furthermore,
5-ARIs reduce the risk of acute urinary retention or need
for surgery; in particular dutasteride decreases the risk of
acute urinary retention by 57% and surgical intervention by
48% [17].
To explain why 5-ARIs should be able to reduce prostate
bleeding during surgery and recovery, we have to look to the
decrease in blood vessel number that accompanies the
shrinking of the prostate [18]. This conclusion can also be
extrapolated from many studies reporting a significant
decrease in gross haematuria secondary to benign prostatic
enlargement [19,20]. However, when looking at specific studies
on decreased bleeding during endoscopic surgery, there are
conflicting results.
Focusing on trials using dutasteride as the 5-ARI,
Boccon-Gibod et al. [21], in a multicentre study with 59
patients randomised to receive 4 weeks of daily placebo or
0.5 mg dutasteride, reported no significant difference in
bleeding between groups (1.4 vs 1.9 Hb/g resected tissue). In
the experience of Hahn et al. [22], there was no significant
reduction in bleeding between patients receiving a treatment
before surgery with 2–4 weeks dutasteride vs placebo. On the
other hand, Kravchick et al. [23] reported that 6 weeks
dutasteride treatment can reduce, in the periurethral area
proximal to the verumontanum, prostate tissue vascularity.
Also the Martov et al. [24] study, which included 70 patients
with large prostates (>80 mL) treated with ≥1 month
dutasteride before TURP, noted a reduction in blood loss and
operative time together with an increase in removed tissue.
Pastore et al. [25], from their experience, suggested that
pretreatment with dutasteride for 6 weeks could considerably
reduce bleeding during TURP.
The results of our present trial are novel and are an important
contribution to the understanding of the ability of 5-ARIs to
reduce bleeding during endoscopic surgery. Firstly, our
present trial represents a step forward because is it one of the
few considering dutasteride as the 5-ARI (dual inhibition) and
also because we analysed a large number of patients (240
randomised patients). Furthermore, we are the first to find a
direct correlation between bleeding and the size of the
prostate adenoma. Focusing on prostate size, there are only a
few published papers stressing the relation between the size
and the effect against LUTS: finasteride is effective only when
treating prostates >40 mL and dutasteride is also efficacious
when considering a volume of 30 mL [26,27]. In particular,
in order to categorise and to make our findings more
homogeneous, we decided to divide our groups according to
prostate volume. Considering prostates with a volume of
<50 mL we noted no statistically significant difference in Hb
and Ht between the placebo- and dutasteride-treated groups;
conversely, when considering large prostates (≥50 mL), there
was a statistically significant difference in the reduction in
blood counts when comparing the treatment and placebo
groups.
To evaluate angiogenesis and vascularisation of the prostate,
we evaluated VEGF, which stimulates proliferation and
migration of endothelial cells playing a role in physiological
and pathological angiogenesis, and CD34, a glycosylated type I
transmembrane protein expressed in the luminal surface of
most endothelial cells of small vessels. Zaitsu et al. [28]
in their paper, report that dutasteride is able to reduce the
vascularisation of the prostate. In particular, they analysed
prostate sections stained with haematoxylin/eosin and
anti-CD31 antibody, finding that artery/arteriole density and
vein/venule density in benign prostatic tissue were lower in
the 5-ARI-treated group. Pareek et al. [29] conducted a study
to elucidate the mechanism by which finasteride reduces
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prostatic urethral bleeding and concluded that decreased
expression of VEGF inhibits angiogenesis and significantly
decreases MVD in prostatic suburethral tissue.
Our present results are also divided by the size of the prostate
because we again noted a correlation with the volume of the
gland. Considering prostates with a volume of <50 mL, the
VEGF index and CD34 values reported do not differ in a
statistically significant way between patients treated with
placebo or 5-ARI.When looking at prostates with a volume of
≥50 mL, our present findings confirm a statistically significant
difference in the VEGF index and CD34 values between the
two groups.
Although this is a randomised study, there is some potential
biases that could represent some limitations: patient’s physical
features, such as coagulation and body mass index, histological
analysis of the resected tissue, surgical duration and quality.
In conclusion, dutasteride, 0.5 mg daily for 8 weeks, is able to
reduce operative and perioperative bleeding in patients
submitted to B-TURP only if a large prostate (≥50 mL) is
being treated. Our findings are confirmed by Hb and Ht values
reported before and after the B-TURP and by reductions in
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